Mireia M. V.
- Country
- Spain
- Department
- Oncology
Research Overview
- Efficacy and Safety of Giredestrant vs. Fulvestrant with CDK4/6 Inhibitor in ER+ HER2- Advanced Breast Cancer Resistant to Endocrine Therapy
- A Phase II Randomized, Double-Blind Study Comparing Fulvestrant and Palbociclib Versus Fulvestrant and Placebo in HR-Positive Metastatic Breast Cancer
- A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease
Data & Insights
Has run more than one trial at 194 of 425 partner sites.
Specializations
Early-Stage Breast Cancer Research
This investigator specializes in studying hormone receptor-positive (HR+) and HER2-negative early breast cancer, conducting innovative therapeutic trials with novel treatment approaches. Their research encompasses the evaluation of adjuvant endocrine therapy combinations and treatment strategies for early-stage disease management.
- Hormone Receptor-Positive Disease Management
- Early-Stage Treatment Optimization
- Adjuvant Therapy Evaluation
Advanced Breast Cancer Studies
The investigator focuses on developing treatments for metastatic breast cancer, particularly investigating novel therapeutic combinations for ER-positive, HER2-negative advanced disease. Their work includes evaluation of targeted therapies and innovative drug combinations for patients with advanced disease.
- Metastatic Disease Treatment
- Novel Drug Combinations
- Brain Metastases Management
Triple-Negative Breast Cancer Research
Research initiatives include investigating innovative approaches for triple-negative breast cancer (TNBC) treatment, with particular emphasis on immunotherapy combinations and post-neoadjuvant treatment strategies. The investigator studies personalized treatment approaches based on tumor characteristics.
- Immunotherapy Applications
- Post-Neoadjuvant Treatment
- Biomarker-Guided Therapy
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.